Controlling ACE and ARB Dosing Can Benefit Treatment of Chronic Kidney Disease

In a Pharmacy Times® interview, Chi Chu, MD, an assistant professor in the division of nephrology at the University of California San Francisco, spoke about his 2021 ASN Kidney Week presentation on the submaximal dose of angiotensin converting enzyme (ACE) inhibitor and angiotensin II receptor blockers (ARB) for individuals with proteinuria.

He discussed how ACE and ARB therapies can be applied to chronic kidney disease, and the benefits of controlling the dosage.